

Securing the Azacitidine (Vidaza®) Circuit in Home Hospitalisation

Maljean L¹, Sereni C¹, Morey F¹, Mauguén B¹, Feyeux A², Bonnefous JL¹

¹ Pôle pharmacie, CH Bourg-en-Bresse, France ; ² Service HAD, CH Bourg en Bresse, France

Introduction: Azacitidine

Treatment of haematological malignancies
75mg/m² subcutaneously **for 7 days**
Stability after reconstitution : **45 minutes** at 25°C,
8 hours between 2 and 8 °C , **8 jours** à -20°C [1]

Treatment in day hospitalisation
constraining for patients → Home
hospitalisation circuit involving
more and more patients:
19 patients in 2019


Objective: to secure the Azacitidine
circuit, an **expensive** and **highly**
heat-sensitive molecule, in order to
optimize patient care

Materiel and methods:

Creation of a working group on securing chemotherapy circuit in Home hospitalisation involving:

- CRU pharmaceutical team
- Home Care practitioner
- Haematology health executive

Results:



Conclusion:

In order to improve patient management, an Home hospitalisation circuit has been established for Azacitidine. Safety actions centred on healthcare personnel training and patient education, have been implemented at each stage of the circuit for this sensitive molecule. Other action are planned: use of temperature verification tracers in patients 'home, etc.